CBD against pain

How does CBD work against acute and chronic pain?

Cannabidiol (CBD), a non-psychoactive cannabinoid from the hemp plant, shows promising mechanisms of action for both acute and chronic pain. The pain-relieving effect is based on a combination of anti-inflammatory, neuroprotective, and modulatory effects on the endocannabinoid system and other pain-mediating systems of the body.

Scientifically, it is essential to distinguish between:

Pure CBD (isolated)

• Non-psychoactive
• Weak or inconsistent analgesic effects in human studies with monotherapy
• Limited effectiveness at high doses (e.g., ≥300–600 mg/day)

CBD in combination with THC (e.g., Nabiximols/Sativex®)

• THC is primarily analgesic (CB1 agonism)
• CBD acts modulatory (e.g., on THC side effects) and anti-inflammatory
• Clinically effective for neuropathic or tumor-associated pain (e.g., MS, cancer)

Influence on the endocannabinoid system (ECS)

The human endocannabinoid system regulates pain perception, inflammatory responses, and neuronal signal transmission. CBD interacts indirectly with the CB1 and CB2 receptors:

• CB1 receptors are mainly located in the central nervous system and are involved in pain processing.
• CB2 receptors are predominantly found on immune cells and modulate inflammation.

CBD does not bind directly to these receptors but influences their activity, for example by inhibiting the enzyme FAAH (Fatty Acid Amide Hydrolase)which breaks down the body's own cannabinoid anandamide. Higher anandamide levels lead to a reduction in pain perception.

Anti-inflammatory action as indirect pain relief

Chronic pain, e.g., in arthritis or fibromyalgia, is often inflammation-related. CBD inhibits inflammatory processes by:

• Reduction of proinflammatory cytokines such as TNF-α or IL-6
• Influence on NF-κBa central transcription factor for inflammatory responses
• Modulation of the TRPV1 receptor (also known as the vanilloid receptor), which is involved in nociceptive (painful) signals

Neuromodulatory effects in chronic pain

CBD acts on various non-cannabinoid receptors, including:

• TRPV1 receptorsthat detect pain, temperature, and inflammatory stimuli
• 5-HT1A receptorsthat are part of the serotonergic system and have pain-modulating effects
• GPR55 receptors, which play a role in pain signal transmission

These interactions can weaken the neuronal transmission of pain impulses and contribute to long-term pain modulation – especially in neuropathic pain.

Psychological component of chronic pain

Chronic pain is often associated with psychological burdens such as stress, anxiety or sleep disorders. CBD can contribute to the indirect improvement of pain perception through anxiolytic and sleep-promoting properties by stabilizing overall well-being.

What types of pain can be alleviated with CBD?

Cannabidiol (CBD) shows broad therapeutic potential in pain therapy – especially for chronic, inflammatory, and neuropathic pain. The effectiveness varies depending on the type of pain, intensity, individual sensitivity, as well as the chosen CBD dosage and form.

Chronic pain

CBD was able to relieve chronic pain with various causes. The main focus is on:

• Arthritis and rheumatism: Here, CBD molecules inhibit inflammatory mediators such as TNF-α and IL-1β, leading to pain relief.
• Fibromyalgia: Patients with generalized muscle pain report improvements through CBD, among other things by acting on the serotonergic system.
• Back pain and muscle pain: CBD can reduce local muscle tension and inflammation – applied orally or topically.

Scientific background: In an observational study with over 2,700 participants, 62% reported a significant reduction in chronic pain through CBD (Corroon et al., 2018).

Neuropathic pain

These arise from damage or malfunction of nerve fibers and are considered particularly difficult to treat. CBD can help here by:

• Modulation of TRPV1 and GPR55 receptors
• Increase of endocannabinoids anandamide
• Inhibition of glutamatergic overexcitation

…produce noticeable relief. Typical conditions include:

• Diabetic Neuropathy
• Multiple Sclerosis (MS)
• Postoperative Nerve Pain
• Phantom Pain

Study Example: A clinical study with a THC/CBD combination preparation (Nabiximols) in MS patients showed significant improvements in neuropathic pain (Notcutt et al., 2012).

Inflammation-Related Pain

CBD exerts anti-inflammatory effects by influencing cytokines, chemokines, and intracellular signaling pathways. Therefore, it is potentially effective for:

• Crohn's Disease, Ulcerative Colitis (IBD)
• Psoriatic Arthritis
• Chronic Wound Pain

CBD here not only acts as a pain reliever but can also reduce the underlying inflammatory process.

Menstrual Complaints and Vaginal Dryness

CBD can relieve menstrual pain (dysmenorrhea) through antispasmodic and anti-inflammatory mechanisms. Women also report improvements in PMS-associated pain in the lower abdomen, back, and breast area. CANNEFF Suppositories are medical products used for pain and discomfort in the intimate area.

Headaches and Migraines

The data is limited, but some studies show that CBD, through modulation of serotonin receptors (5-HT1A) and inhibition of neuroinflammatory processes, in:

• Tension headaches
• Migraine
• Cluster headaches

can have a supportive effect – often in combination with THC.

Pain in cancer patients

In palliative care, CBD is used to relieve tumor pain, chemotherapy-induced neuropathy, and bone pain. The effect can be enhanced in combination with THC.

Note: CBD does not replace classic pain therapy but can sensibly complement it – especially in therapy resistance or as an accompanying measure. 

Is CBD an alternative to painkillers?

Cannabidiol (CBD) is increasingly discussed as a possible alternative or complement to classic painkillers. However, whether CBD a real alternative to analgesics like NSAIDs (non-steroidal anti-inflammatory drugs), paracetamol, or opioids represents depends on various factors – especially the type of pain, the severity of symptoms, and individual response.

CBD as a complementary or alternative pain therapy?

CBD does not act through the classic pain-relieving mechanisms such as COX inhibition (NSAIDs) or opioid receptors. Instead, it modulates:

• the endocannabinoid system (e.g., by inhibiting anandamide degradation),
• inflammatory signaling pathways (e.g., via TNF-α, IL-6),
• neurological pain processing (e.g., via TRPV1, 5-HT1A, and GPR55 receptors).

Conclusion: CBD does not replace classic painkillers in acute situations (e.g., after surgeries or severe injury) not, but can an effective supplement for chronic or inflammatory-neuropathic pain represent.

Scientific evidence on the efficacy of CBD compared to painkillers

chronic pain

A meta-analysis (Häuser et al., 2018) showed that CBD-containing preparations – often in combination with THC – have moderate effects on chronic pain, especially in:

• neuropathic pain
• pain associated with multiple sclerosis
• rheumatic diseases

This effect was comparable to classic NSAIDs in many cases, but with a more favorable side effect profile.

CBD vs. opioids

In severe pain (e.g., cancer pain) CBD is not sufficiently effective, but can:

• the reduce necessary opioid dose ("opioid-sparing effect"),
• alleviate side effects such as nausea or constipation,
• slow down tolerance-forming processes.

A study by Abrams et al. (2011) suggests that patients with chronic pain on opioid medication experience through CBD-containing cannabis extracts a enhanced pain relief without increasing opioid dosage experienced.

Comparison: CBD and classic painkillers

Safety and tolerability

A major advantage of CBD lies in the high tolerability and the low side effect profile:

• no sedative effect at normal dosage
• no development of dependency
• hardly any gastrointestinal side effects
• possible side effects: dry mouth, fatigue, interactions with medications (especially via CYP450 enzymes)

Current medical consensus

CBD is not a complete alternative to classical painkillers in acute medicine, but can in the long-term pain therapy – especially for chronic, inflammatory, and neuropathic pain – an effective, better tolerated supplement represent. Medical supervision and individual dose adjustment are essential here.

CBD is currently not recommended as a full substitute for painkillers, but as complementary measure for chronic pain increasingly appreciated – especially in patients who:

• poorly tolerated classical painkillers,
• suffering from side effects,
• seeking multimodal therapies (e.g., for fibromyalgia or endometriosis).

How quickly does the pain-relieving effect of CBD take effect?

The speed at which CBD develops a pain-relieving effect depends significantly on the Form of administration, the individual metabolic rate, the Type of pain (acute vs. chronic) as well as the dose compared to classic painkillers like ibuprofen or paracetamol, CBD works not immediate and not equally strong for everyone – its effects often build up gradually and are especially within a regular intake noticeable.

Influence of the form of administration on the onset of action

Acute vs. chronic pain

• In acute pain (e.g., injuries, headaches) the effect is usually weaker and delayed. Studies show that CBD here often cannot compete with the rapid effectiveness of classic analgesics.
• In chronic pain (e.g., arthritis, neuropathy) CBD unfolds its effect slowly over days to weeks, because it anti-inflammatory, neuroprotective, and regulating the endocannabinoid system works.

Example: In chronic inflammatory diseases such as rheumatoid arthritis, a noticeable improvement in pain was observed in clinical studies after 2–4 weeks of regular intake determined (Blake et al., 2006).

Influence of dosage and individual biochemistry

• The individual body mass, liver enzymes, distribution of CB1 and CB2 receptors as well as genetic factors influence the onset of action.
• Too low dosages can initially ineffective be, which is why a “Titration approach“ (start low, increase slowly) is recommended.
• The Effective level in the blood with regular intake more stable, thereby making the effect intensified and appears earlier.

Subjective pain perception

CBD also influences psychological factors such as Stress, sleep quality, and mood, which can indirectly improve pain perception. Those affected thus perceive the relief not always immediately consciously perceived, but experience it as gradual relief.

Which forms of CBD are suitable for pain?

The most suitable form of CBD administration for pain depends heavily on Type of pain, location of complaints, and therapy goal from:

• Sublingual drops and Capsules are ideal for systemic and chronic pain.
• Topical preparations act specifically locally on muscle or joint pain.
• Suppositories are especially suitable for pelvic pain and gynecological complaints, pain during sex, as well as diseases and pain at the anus and rectum (anal fissures, hemorrhoids, anal vein thromboses, etc.).
• Inhalation should only be used in exceptional cases.

An individual therapeutic trial with medical supervision is advisable to determine the optimal application form.

What studies demonstrate the effectiveness of CBD against pain?

The study situation shows that CBD – alone or in combination with THC – in various types of pain such as chronic, neuropathic, inflammatory, and even tumor-associated pain can have a clinically relevant effect, but also may not. Especially in chronic pain with inflammatory or nervous component the data situation is solid. Acute pain has been less well studied so far.

What dosage of CBD is sensible for pain?

Currently, there is no confirmed dose that can be used as a standard for pain medication. 

The commonly recommended "starting dose" of 10–30 mg CBD/day is no evidence-based medical standard, but originates:

• from marketing strategies of the industry,
• from legal restrictions for over-the-counter CBD products (e.g., dietary supplements),
• and is often on layperson portals or by influencers spread without medical training.

Such recommendations convey a false sense of security, but are medically not relevant for real pain patients. Many patients try CBD at these low dosages – without effect – and give up on, although a therapeutically meaningful effect at 200–400 mg/day (and higher) can only be applied. And that the real studies show.

Some studies, such as those by Mücke et al. (2018), suggest that a combination of THC and CBD can provide pain relief in certain patients, but with potential side effects.

Are there side effects when taking CBD for pain?

Yes, cannabidiol (CBD) can – despite its generally good tolerability – cause side effects, especially with higher dosage, at Long-term use or in Combination with other medications. The side effects are generally mild to moderate, but not to be underestimated, especially in clinical use with pain patients.

Drug interactions (CYP450)

CBD inhibits various isoenzymes of the cytochrome P450 system (e.g. CYP3A4, CYP2C19), which can slow down the breakdown of many drugs. This can lead to increased drug levels and side effects – e.g. with:

• Opioids (e.g. Morphine)
• Antidepressants (e.g. Citalopram, Sertraline)
• Antiepileptics (e.g. Clobazam, Valproate)
• NSAIDs (e.g. Diclofenac, Ibuprofen)

Summary: Benefits and side effects in relation

What do reviews say about CBD for pain?

experience reports on the use of Cannabidiol (CBD) for pain mainly come from surveys, patient forums, online reviews, and observational studies without control groups. Although these reports do not provide clinical evidence in the strict sense, they provide important indications of subjective effectiveness, usage habits, tolerability and patient satisfaction – especially in chronic pain syndromes. Experience reports show that many pain patients subjectively benefit from CBD, especially in chronic, inflammatory, or stress-associated pain. The positive feedback concerns not only pain but also sleep and mental stability. A binding therapeutic statement can, however, cannot be derived – controlled studies are required for this.

Conclusion

Cannabidiol (CBD) is no classic analgesic in the pharmacological sense and shows has no immediate pain-relieving effect in acute pain. However, it proven anti-inflammatory, immunomodulatory, and anxiolytic properties occurs, whereby especially inflammatory and stress-associated types of pain can be positively influenced.

Furthermore, studies show indications that CBD in combination with other substances – especially opioids or THC-containing cannabinoids – whose analgesic effect can enhance ("opioid-sparing effect"). This pharmacodynamic synergy can enable reducing the dosage of conventional painkillerswhich in turn leads to Minimization of side effects and dependency risks contributes.

In summary: CBD is not a primary pain medication, but can be within the framework of a contribute as an add-on therapy to pain reduction, especially in chronic inflammatory or neuropathic pain syndromes – provided that the application is controlled and evidence-based.

Sources

Devinsky, O., Cross, J. H., & Wright, S. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The New England journal of medicine, 377(7), 699–700. https://doi.org/10.1056/NEJMc1708349

Iffland, K., & Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and cannabinoid research, 2(1), 139–154. https://doi.org/10.1089/can.2016.0034

Gaston, T. E., Bebin, E. M., Cutter, G. R., Liu, Y., Szaflarski, J. P., & UAB CBD Program (2017). Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia, 58(9), 1586–1592. https://doi.org/10.1111/epi.13852

Russo E. B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and clinical risk management, 4(1), 245–259. https://doi.org/10.2147/tcrm.s1928

Baron E. P. (2015). Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. Headache, 55(6), 885–916. https://doi.org/10.1111/head.12570

Fine, P. G., & Rosenfeld, M. J. (2013). The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides medical journal, 4(4), e0022. https://doi.org/10.5041/RMMJ.10129

De Gregorio, D., McLaughlin, R. J., Posa, L., Ochoa-Sanchez, R., Enns, J., Lopez-Canul, M., Aboud, M., Maione, S., Comai, S., & Gobbi, G. (2019). Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain, 160(1), 136–150. https://doi.org/10.1097/j.pain.0000000000001386

Pergolizzi, J. V., Jr, Lequang, J. A., Taylor, R., Jr, Raffa, R. B., Colucci, D., & NEMA Research Group (2018). The role of cannabinoids in pain control: the good, the bad, and the ugly. Minerva anestesiologica, 84(8), 955–969. https://doi.org/10.23736/S0375-9393.18.12287-5

Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004). Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia, 59(5), 440–452. https://doi.org/10.1111/j.1365-2044.2004.03674.x

Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology, 68(7), 515–521. https://doi.org/10.1212/01.wnl.0000253187.66183.9c

Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018). Cannabinoids and Pain: New Insights From Old Molecules. Frontiers in pharmacology, 9, 1259. https://doi.org/10.3389/fphar.2018.01259

Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2018). A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Frontiers in pharmacology, 9, 1365. https://doi.org/10.3389/fphar.2018.01365

Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford, England), 45(1), 50–52. https://doi.org/10.1093/rheumatology/kei183

Zhornitsky, S., & Potvin, S. (2012). Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel, Switzerland), 5(5), 529–552. https://doi.org/10.3390/ph5050529

Ueberall, M. A., Essner, U., & Mueller-Schwefe, G. H. (2019). Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. Journal of pain research, 12, 1577–1604. https://doi.org/10.2147/JPR.S192174

Heineman, J. T., Forster, G. L., Stephens, K. L., Cottler, P. S., Timko, M. P., & DeGeorge, B. R., Jr (2022). A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. The Journal of hand surgery, 47(7), 611–620. https://doi.org/10.1016/j.jhsa.2022.03.002

Polidoro, D., Temmerman, R., Devreese, M., Charalambous, M., Ham, L. V., Cornelis, I., Broeckx, B. J. G., Mandigers, P. J. J., Fischer, A., Storch, J., & Bhatti, S. F. M. (2022). Pharmacokinetics of Cannabidiol Following Intranasal, Intrarectal, and Oral Administration in Healthy Dogs. Frontiers in veterinary science, 9, 899940. https://doi.org/10.3389/fvets.2022.899940

Schmiedhofer, P., Vogel, F. D., Koniuszewski, F., & Ernst, M. (2022). Cys-loop receptors on cannabinoids: All high?. Frontiers in physiology, 13, 1044575. https://doi.org/10.3389/fphys.2022.1044575

Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H., & Ehler, E. (2014). A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European journal of pain (London, England), 18(7), 999–1012. https://doi.org/10.1002/j.1532-2149.2013.00445.x

Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of pain and symptom management, 39(2), 167–179. https://doi.org/10.1016/j.jpainsymman.2009.06.008

Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D. C., Thomas, E. M., Astbury, D., Freeman, A. M., Lees, R., Craft, S., Morrison, P. D., Bloomfield, M. A. P., O'Ryan, D., Kinghorn, J., Morgan, C. J. A., Mofeez, A., & Curran, H. V. (2020). Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The lancet. Psychiatry, 7(10), 865–874. https://doi.org/10.1016/S2215-0366(20)30290-X

Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. The Cochrane database of systematic reviews, 3(3), CD012182. https://doi.org/10.1002/14651858.CD012182.pub2

Pramhas, S., Thalhammer, T., Terner, S., Pickelsberger, D., Gleiss, A., Sator, S., & Kress, H. G. (2023). Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. The Lancet regional health. Europe, 35, 100777. https://doi.org/10.1016/j.lanepe.2023.100777

Bhaskar, A., Bell, A., Boivin, M., Briques, W., Brown, M., Clarke, H., Cyr, C., Eisenberg, E., de Oliveira Silva, R. F., Frohlich, E., Georgius, P., Hogg, M., Horsted, T. I., MacCallum, C. A., Müller-Vahl, K. R., O'Connell, C., Sealey, R., Seibolt, M., Sihota, A., Smith, B. K., … Moulin, D. E. (2021). Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. Journal of cannabis research, 3(1), 22. https://doi.org/10.1186/s42238-021-00073-1

Vela, J., Dreyer, L., Petersen, K. K., Arendt-Nielsen, L., Duch, K. S., & Kristensen, S. (2022). Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain, 163(6), 1206–1214. https://doi.org/10.1097/j.pain.0000000000002466

Gulbransen, G., Xu, W., & Arroll, B. (2020). Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP open, 4(1), bjgpopen20X101010. https://doi.org/10.3399/bjgpopen20X101010

Dahlgren, Mary & Smith, Rosemary & Kosereisoglu, Deniz & Sagar, Kelly & Lambros, Ashley & El-Abboud, Celine & Gruber, Staci. (2024). A survey-based, quasi-experimental study assessing a high-cannabidiol suppository for menstrual-related pain and discomfort. npj Women's Health. 2. 10.1038/s44294-024-00032-0.https://www.nature.com/articles/s44294-024-00032-0